Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

We reported new preclinical findings with our IMGN901 and IMGN242 product candidates at the AACR 2008 annual meeting.

Find out about more of our pipeline compounds...

ImmunoGen’s Tumor-Activated Prodrug (TAP) technology can expand the potential of monoclonal, or manufactured, antibodies in the treatment of cancer.

Learn how it works...

5/1/2008
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2008 Financial Results

4/8/2008
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research 2008 Annual Meeting

Read our releases...

built@zoomedia.com

Last updated May 1, 2008